Treatment approaches for patients with TP53-mutated mantle cell lymphoma

Thomas E. Lew; Adrian Minson; Michael Dickinson; Sasanka M. Handunnetti; Piers Blombery; Amit Khot; Mary Ann Anderson; David Ritchie; Constantine S. Tam; John F. Seymour

doi:10.1016/s2352-3026(22)00355-6

Related publications

Article2021

T-Cell Replete Allogeneic Stem Cell Transplant Is an Effective Treatment Option for Patients with TP53 mutated Mantle Cell Lymphoma

Edward R. Scheffer Cliff, Thomas E. Lew, Piers Blombery, Michael Dickinson, Constantine S. Tam, John F. Seymour, Ashish Bajel, David Ritchie, Amit Khot

Letter2021

T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease

Thomas E. Lew, Edward R. Scheffer Cliff, Michael Dickinson, Constantine S. Tam, John F. Seymour, Piers Blombery, Ashish Bajel, David Ritchie, Amit Khot

Article2023

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in <i>TP53</i> -mutated disease

Thomas E. Lew, Edward R. Scheffer Cliff, Michael Dickinson, Constantine S. Tam, John F. Seymour, Piers Blombery, Ashish Bajel, David Ritchie, Amit Khot

Article2008

Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract

Spyridon Michopoulos, Kalliopi Petraki, Charis Matsouka, Efstathios Kastritis, Heleni Chrysanthopoulou, Meletios A Dimopoulos

Article2023

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson